CRISPR screen identifies new cancer target

Deletion of DHX9 activates innate immune response and decreases the growth of "cold" tumours like SCLC.

By: Gorm Palmgren - Jan. 9, 2024

#CRISPRMED24

Researchers at Fox Chase Cancer Center, Philadelphia, have used CRISPR-based screening to show that DHX9 potently represses the innate immune response in small cell lung cancer (SCLC) cells through double-stranded RNA (dsRNA) repression.

DHX9 was then depleted in vivo by an inducible system in SCLC cells implanted into mice. Upon induction, dsRNA accumulated and triggered an innate immune response, resulting in a more immunogenic tumour microenvironment. Increased DNA damage and replication stress in SCLCs led to decreased tumour growth.

The research provides a new perspective on treating "cold" tumours like SCLC that typically elicit a weak or non-existent immune response. Targeting DHX9 can make these tumours more responsive to immunotherapies and offers a novel strategy in cancers where traditional therapies have limited effectiveness.

The study was led by Israel Cañadas Castillo and the paper was published yesterday in Cancer Discovery. You can read it here.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagMissing linksHashtagNewsHashtagCRISPR Therapeutics AG

News: CRISPR screen identifies new cancer target
News: CRISPR screen identifies new cancer target
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine